Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study

被引:33
作者
Stacchiotti, S. [1 ]
Simeone, N. [2 ]
Lo Vullo, S. [3 ]
Morosi, C. [4 ]
Greco, F. G. [4 ]
Gronchi, A. [5 ]
Barisella, M. [6 ]
Collini, P. [6 ]
Zaffaroni, N. [7 ]
Dagrada, G. P. [6 ]
Frezza, A. M. [1 ]
Mariani, L. [3 ]
Casali, P. G. [1 ,8 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Unit 2, Dept Med Oncol, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Unit Clin Epidemiol & Trial Org, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Radiol, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Sarcoma Unit, Dept Surg, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Diagnost Pathol & Lab Med Dept, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Mol Pharmacol Unit, Dept Expt Oncol & Mol Med, Milan, Italy
[8] Univ Milan, Med Oncol & Hematooncol Dept, Milan, Italy
关键词
Sarcoma; Solitary fibrous tumour; Hemangiopericytoma; Target therapy; Antiangiogenic; Axitinib; PAZOPANIB; HEMANGIOPERICYTOMA; CHEMOTHERAPY; TEMOZOLOMIDE; SUNITINIB; RECURRENT; SARCOMA;
D O I
10.1016/j.ejca.2018.10.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To explore the activity of axitinib in advanced solitary fibrous tumour (SFT). Patients and methods: In this investigator-driven phase II study on axitinib in advanced and progressive SFT, patients received axitinib, 5 mg bis in day (BID), until progression or limiting toxicity. Pathologic diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subtypes. The primary end-point was the overall response rate (ORR) by Choi criteria (Choi). Secondary end-points were response by Response Evaluation Criteria in Solid Tumours (RECIST), progression-free survival (PFS) and overall survival (OS). Results: From April 2015 and October 2017, 17 eligible patients entered the study (metastatic: 17; SFT subtype: 13 M-SFT, 4 HG/D-SFT; prior treatment: 9 antiangiogenics, 5 cytotoxics). All patients were evaluable for response. The best Choi response was seven partial response (PR) (ORR, 41.2%), six stable disease (SD) and four progressions. Choi-ORR was 54% (7/13) when only M-SFTs were considered. Four of seven responsive patients were pretreated with pazopanib. No responses were detected in HG/D-SFT. Best RECIST response was one PR (5.9%), 14 SD and two progressions. Toxicity was as expected. Median Choi-PFS was 5.1 (interquartile range [IQR]: 2.5-14.8) months. Median Choi-PFS was 14.8 (IQR: 5.1-18.0) and 2.8 (IQR: 2.0-5.9) months for patients responsive and non-responsive by Choi, respectively (p = 0.0416). At a 14.4-month median follow-up, median OS was 25.3 months. Conclusion: This study showed that axitinib is active in progressive advanced SFT. One-half of patients carrying the malignant variant of the disease responded, with a >12-month median progression arrest. Responses were better detected with Choi and seen even in patients resistant to other antiangiogenics. Tolerability was good. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 22 条
  • [1] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [2] Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour
    Constantinidou, Anastasia
    Jones, Robin L.
    Olmos, David
    Thway, Khin
    Fisher, Cyril
    Al-Muderis, Omar
    Judson, Ian
    [J]. ACTA ONCOLOGICA, 2012, 51 (04) : 550 - U163
  • [3] Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation
    Dagrada, Gian P.
    Spagnuolo, Rosalin D.
    Mauro, Valentina
    Tamborini, Elena
    Cesana, Luca
    Gronchi, Alessandro
    Stacchiotti, Silvia
    Pierotti, Marco A.
    Negri, Tiziana
    Pilotti, Silvana
    [J]. MODERN PATHOLOGY, 2015, 28 (08) : 1074 - 1083
  • [4] Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience
    DeVito, Nicholas
    Henderson, Evita
    Han, Gang
    Reed, Damon
    Bui, Marilyn M.
    Lavey, Robert
    Robinson, Lary
    Zager, Jonathan S.
    Gonzalez, Ricardo J.
    Sondak, Vernon K.
    Letson, G. Douglas
    Conley, Anthony
    [J]. PLOS ONE, 2015, 10 (10):
  • [5] Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour
    Domont, Julien
    Massard, Christophe
    Lassau, Nathalie
    Armand, Jean-Pierre
    Le Cesne, Axel
    Soria, Jean-Charles
    [J]. INVESTIGATIONAL NEW DRUGS, 2010, 28 (02) : 199 - 202
  • [6] Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor
    Ebata, Takahiro
    Shimoi, Tatsunori
    Bun, Seiko
    Miyake, Mototaka
    Yoshida, Akihiko
    Shimomura, Akihiko
    Noguchi, Emi
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Narita, Yoshitaka
    Tamura, Kenji
    [J]. ONCOLOGY, 2018, 94 (06) : 340 - 344
  • [7] Fletcher C. D. M. B. J., 2013, WHO Classification of Tumours of Soft Tissue and Bone, V5
  • [8] Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
    Maruzzo, Marco
    Martin-Liberal, Juan
    Messiou, Christina
    Miah, Aisha
    Thway, Khin
    Alvarado, Rolyn
    Judson, Ian
    Benson, Charlotte
    [J]. CLINICAL SARCOMA RESEARCH, 2015, 5
  • [9] The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis
    Park, Min S.
    Ravi, Vinod
    Conley, Anthony
    Patel, Shreyaskumar R.
    Trent, Jonathan C.
    Lev, Dina C.
    Lazar, Alexander J.
    Wang, Wei-Lien
    Benjamin, Robert S.
    Araujo, Dejka M.
    [J]. CLINICAL SARCOMA RESEARCH, 2013, 3
  • [10] Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor
    Park, Min S.
    Patel, Shreyaskumar R.
    Ludwig, Joseph A.
    Trent, Jonathan C.
    Conrad, Charles A.
    Lazar, Alexander J.
    Wang, Wei-Lien
    Boonsirikamchai, Piyaporn
    Choi, Haesun
    Wang, Xuemei
    Benjamin, Robert S.
    Araujo, Dejka M.
    [J]. CANCER, 2011, 117 (21) : 4939 - 4947